Running for the 3rd year this March 2-4 to unite cross-industry experts from nephrology, cardiology, and endocrinology the 3rd CKD3 Summit is focusing on the question “what’s next?”
Chronic and rare kidney disease drug development has been heating up as stakeholders bustle to deliver benefits beyond SGLT2s. Already in January 2021, Bayer and AstraZeneca have been granted priority review for finerenone and Farxiga respectively.
Dedicated to accelerating more innovative, targeted and clinically effective CKD therapeutics for diabetic and rare kidney diseases, the Chronic Kidney Disease Drug Development Summit (CKD3) is biopharma’s established forum benchmarking, analyzing and troubleshooting beyond the press releases to identify and address drug development opportunity in DN, FSGS, IgA nephropathy lupus nephritis ADPKD, C3G and more.
Running for the 3rd year this March 2-4 to unite cross-industry experts from nephrology, cardiology, and endocrinology the 3rd CKD3 Summit is focusing on the question “what’s next?”, showcasing the latest research transforming renal drug development, including: harnessing the power of artificial intelligence, bioengineering technologies to model renal systems and patient stratification precision medicine.
Access your copy of the Full Event Guide to see the full three days of content and 39 expert speakers.
From academia and regulatory agencies:
- Aliza Thompson, Clinical Team Leader, Division of Cardiovascular & Renal Products, FDA
- Maria Gomez, Professor of Physiology Head, Diabetic Complications Unit Director, Lund University Diabetes Centre (LUDC)
- Matthias Kretzler, Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics, University of Michigan
- Jonathan Himmelfarb, Director of the Kidney Research Institute & Professor of Medicine, University of Washington
- Beno Freedman, Assistant Professor, Nephrology, University of Washington
And from industry:
- Richard Nkulikiyinka, Vice President, Head of Therapeutic Area Cardiology & Nephrology, Bayer Pharmaceuticals
- Jyothis George, Vice President, Clinical, Medical & Regulatory, Novo Nordisk
- Andrew King, Head of Renal Discovery & Translational Medicine, Chinook Therapeutics
- Frank Czerwiec, Chief Medical Officer, Goldfinch Bio
- Matt Breyer, Distinguished Scientist, Janssen
- Seemi Khan, Senior Vice President, Chief Medical Officer, Reata Pharmaceuticals
- Sibylle Hauske, Senior Medical Director & Global Clinical Development Lead – Empagliflozin in CKD, Boehringer Ingelheim
- Borut Cizman, Senior Director & Lead Nephrologist, ASCEND Program, Specialty Pharma, R&D, GSK
- Pernille Hansen, Senior Director & Head of Bioscience, AstraZeneca
- Scott MacDonnell, Associate Director, Cardiovascular & Fibrosis Research, Regeneron Pharmaceuticals
Access your copy of the Full Event Guide
Uniquely positioned to support drug sponsor discussion and networking, CKD3 is industry’s best opportunity to gain actionable insights that further CKD drug development, and the reason why over 50 companies are already signed up to attend, including:
Acceleron Pharma, Allena Pharmaceuticals, AstraZeneca, Bayer, Bio Preventive Medicine, Boehringer Ingelheim, Chinook Therapeutics Inc., Corvidia Therapeutics, Enanta Pharmaceuticals, Foresee Pharmaceuticals, Galapagos NV, Gilead Sciences, GlaxoSmithKline, Goldfinch Biopharma Inc., Horizon Therapeutics plc., IGA Nephropathy Foundation, Inficure Bio, inRegen, Janssen Research & Development, LLC, Johnson & Johnson, Maze Therapeutics, NephCure Kidney International, Novo Nordisk, Otsuka, Pfizer, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Regulus Therapeutics, Renascent Biosciences, TrisaQ, Inc., Tufts Medical Center, Twin City Bio LLC, TwoXAR Pharma
And more.
You can secure your place alongside them here: www.ckd3-summit.com/take-part/register/.
Stay informed, evaluate the landscape, and establish key connections at this unrivalled industry forum for CKD drug sponsors.